Suven Life Sciences Limited

Janssen Pharmaceutica Nv

Matrix Laboratories Limited

Suven Life Science Limited

Ishtiyaque Ahmad

Venkateswarlu Jasti

Ramakrishna Nirogi

Anil Karbhari Shinde

Pradeep Jayarajan

Mark James Wall

Rajagopal Bakthavatchalam

Henricus Jacobus Maria Gijsen

Abdul Rasheed Mohammed

Rama Sastri Kambhampati

Saravanan Vadivelu

Nagaraj Vishwottam Kandikere

Sivaramakrishna Battula

Christopher M Flores

Gopinadh Bhyrapuneni

Ramasastri Kambhampati

Jyothsna Ravula

Sriramachandra Murthy Patnala

Adi Reddy Dwarampudi

Vishwottam Nagaraj Kandikere

Rambabu Namala

Rajesh Kumar Badange

Srinivasa Rao Ravella

Sreedhara Swamy Keshavapura Hosamane

Sangram Keshari Saraf

Ravi Dhamjewar

Gopalan Balasubramanian

Koteshwara Mudigonda

Renny Abraham

Ramkumar Subramaniam

Murlimohan Gampa

Rama Sastri Kambhampti

Kana Ram Kumawat

Reddy Venkat Mekala

Reddy Muddukrishna Chillakur

Rasheed Mohammed

Dhanalakshmi Shanmuganathan

Amol Dinakar Deshpande

Narasimhareddy Gangadasari

Mohmadsadik Abdulhamid Mulla

Veena Reballi

Anil Kashinath Chindhe

Mohamad Sadik Abdulhamid Mulla

Laxman Kota

Padmavathi Kodru

Taraka Naga Vinaykumar Tiriveedhi

Nageshwara Rao Muddana

Ramanatha Shrikantha Saralaya

Srinivas Veeramalla

Taraka Naga Tiriveedhi

Henricus Jacobus Gijsen

Mohamad Sadik Mulla

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R, R, R, and G are defined herein.

Substituted imidazoles as N-type calcium channel blockers

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above compounds of formula (I), and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine Hreceptors.

Compounds as histamine H3 receptor ligands

The present invention relates to novel sulfone compounds as 5-HTreceptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment/prevention of various disorders that are related to 5-HTreceptor functions.

Sulfone compounds as 5-HT6 receptor ligands

The present invention relates to heterocyclyl compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to Histamine Hreceptors, for example cognitive disorders, sleep disorders, obesity and pain. 

[object Object]

The present invention relates to novel bicyclic compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. These compounds are useful in the treatment and prevention of various disorders that are related to &#x3b1;&#x3b2;nicotinic receptors. 

The present invention relates to novel &#x3b1;&#x3b2;neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. The present invention relates to novel &#x3b1;4&#x3b2;2 neuronal nicotinic acetylcholine receptor ligand compounds of the formula (I), and their derivatives, stereoisomers, pharmaceutically acceptable salts and compositions containing them. 

The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.

The present invention provides novel functional assay for 5-HT, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.

Functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1B receptors

The present invention relates to novel aryl indolyl sulfonamide compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them. 

The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined. The present invention relates to compounds of the general formula I their derivatives, their analogs, their tautomeric forms, their stereoisomers, their diastereomers, their bioisosteres, their polymorphs, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them which are predominantly dipeptidyl peptidase IV inhibitors. The present invention also relates to the processes for the preparation of novel compounds of formula (I) and their use in treating type II diabetes and diabetic complications thereof and also for treating dislipidemia, hypercholesterolemia, obesity and hyperglycemia. 

Dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them

Growing community of inventors

Hyderabad Telangana, India

Ishtiyaque Ahmad